SURMOUNT-2 Study Finds Individuals with Type 2 Diabetes and Obesity Lost an Average of 15% of their Body Weight when Taking Tirzepatide

Posted on by

American Diabetes Association Symposium Demonstrates Benefits of Once Weekly Drug for Weight Loss and Glycemic Control SAN DIEGO, June 23, 2023 /PRNewswire/ — Today, findings from SURMOUNT-2, a study of tirzepatide in participants with type 2 diabetes who have obesity were announced,…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.